)
)
)
Ironfist Therapeutics is advancing a new class of nanomedicine radiopharmaceuticals that selectively target tumor associated macrophages. Our precision medicine approach to treat any tumor with TAMs has the potential to change the paradigm in cancer treatment by reprogramming or removing these suppressive cells so the immune system can see the tumor clearly and strike with full force. The nanomedicine component of Tamrada is comparable in size to an antibody fragment, does not leave the vasculature except in tumors, and has renal and biliary clearance without metabolism. 64Cu/177Lu-Tamrada enables precision dosing of cancer patients using a theragnostic approach. 177Lu-Tamrada provides an additional benefit of a bystander effect by killing adjacent tumor cells as demonstrated in preclinical models with clinical trials starting in 2H 2026. The nanomedicine in Tamrada is amendable to modifications to create a pipeline of radiopharmaceuticals with different radioisotopes.
Year Founded
2025
Next catalyst (value inflection) update
Interim clinical results in oncology patients
Expected time of next catalyst update
by end 2026
City
Redwood City
Country
United States
Company CEO or top company official
Jeffrey L Cleland, PhD
Development Phase of Primary Product
Pre-Clinical
Lead Product in Development
Tamrada
Number of Unlicensed Products
1
Therapeutic Area
Oncology
Website
http://www.ironfisttx.com
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
